Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma.
Melanoma is an immunoresponsive malignancy. Interleukin-10 (IL-10) is a potent regulator of immunosuppression. The purpose of this research was to define the relationship of serum IL-10 to survival in patients with metastatic melanoma. Forty-one melanoma patients and 50 normal volunteers were analyzed. The median IL-10 level as determined by enzyme-linked immunosorbent assay (ELISA) in melanoma patients was 8.75 pg/ml compared to < 3.0 pg/ml in normal volunteers (p = 0.0001). Survival of melanoma patients with an IL-10 level above 10.0 pg/ml was 365 days compared to 557 days in patients with IL-10 levels less than 10.0 pg/ml (p = 0.0259, Wilcoxon). Elevated IL-10 levels were correlated with poor survival.
Nemunaitis
J
J
Baylor University Medical Center, Dallas, Texas, USA. John.Nemunaitis@USOncology.com
Fong
T
T
Shabe
P
P
Martineau
D
D
Ando
D
D
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D008297:Male; D008545:Melanoma / Q000097:blood*; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000097:blood*; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D016753:Interleukin-10